4 results
• To assess the long-term bronchodilation of aclidinium/formoterol FDCs compared to individual components and placebo, when administered twice daily via inhalation to COPD patients.• To assess the benefits of aclidinium/formoterol FDCs in COPD…
To provide continued treatment with trametinib.
Part 1 primary objectives: To determine the safety, tolerability and range of tolerated combination doses in subjects with BRAF-V600E mutation-positive CRC intwo dosing groups:* dabrafenib dosed orally in combination with panitumumab * trametinib…
Primary: efficacy of dabrafenib and trametinib combination therapy compared to placebo with respect to relapse-free survival in patients with completely resected, histologically confirmed, BRAF V600E/K high risk, stage III cutaneous melanoma.…